




Make your **mark.**

Discover reagents that make your research stand out.

DISCOVER HOW



Correction: MyD88: A critical adaptor protein in innate immunity signal transduction

This information is current as of July 2, 2022.

N. Warner and G. Núñez

J Immunol 2013; 190:3824; ;

doi: 10.4049/jimmunol.1390010

<http://www.jimmunol.org/content/190/7/3824>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at: <http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at: <http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: <http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



Corrections

Warner, N., and G. Núñez. 2013. MyD88: A critical adaptor protein in innate immunity signal transduction. *J. Immunol.* 190: 3–4.

On page 3, the reference cited in the sentence “Shortly afterward, by using overexpression studies, Medzhitov et al. (3) showed that MyD88 is critical for TLR signaling” was incorrect. The correct reference is:

Medzhitov, R., P. Preston-Hurlburt, E. Kopp, A. Stadlen, C. Chen, S. Ghosh, and C. A. Janeway, Jr. 1998. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. *Mol. Cell.* 2: 253–258.

In addition, there was another article with the same conclusion published around the same time that we inadvertently failed to cite:

Muzio, M., G. Natoli, S. Saccani, M. Levrero, and A. Mantovani. 1998. The human toll signaling pathway: Divergence of nuclear factor κ B and JNK/SAPK activation upstream of tumor necrosis factor receptor–associated factor 6 (TRAF6). *J. Exp. Med.* 187: 2097–2101.

www.jimmunol.org/cgi/doi/10.4049/jimmunol.1390010